In an attempt to expand its rare disease portfolio, BioMarin has agreed to acquire Amicus Therapeutics for a total equity value of approximately US$4.8 B. Through this strategic takeover, BioMarin picks up access to commercial assets, Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease. The deal provides BioMarin with a complementary addition of enzyme therapies to its existing portfolio as well as the opportunity to expand the global footprint of Galafold and Pombiliti + Opfolda.